Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

921 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Corrigendum to "Extracellular matrix modulates depot-specific adipogenic capacity in adipose tissue of dairy cattle" (J. Dairy Sci. 107:9978-9996).
Fiallo Diez JF, Tegeler AP, Flesher CG, Michelotti TC, Ford H, Hoque MN, Bhattarai B, Benitez OJ, Christopher GF, Strieder-Barboza C. Fiallo Diez JF, et al. Among authors: ford h. J Dairy Sci. 2025 Jan;108(1):1156-1158. doi: 10.3168/jds.2024-108-1-1156. J Dairy Sci. 2025. PMID: 39725498 Free article. No abstract available.
MIRO2 promotes cancer invasion and metastasis via MYO9B suppression of RhoA activity.
Boulton DP, Hughes CJ, Vaira V, Del Gobbo A, Palleschi A, Locatelli M, Danis E, Raza M, Neumann AJ, Purdy SC, Lerma R, Meshki J, Ford HL, Prekeris R, Morrissey C, Caino MC. Boulton DP, et al. Among authors: ford hl. Cell Rep. 2024 Dec 24;44(1):115120. doi: 10.1016/j.celrep.2024.115120. Online ahead of print. Cell Rep. 2024. PMID: 39723893 Free article.
Optical coherence tomography in secondary progressive multiple sclerosis: cross-sectional and longitudinal exploratory analysis from the MS-SMART randomised controlled trial.
De Angelis F, Cameron JR, Eshaghi A, Parker R, Connick P, Stutters J, Plantone D, Doshi A, John N, Williams T, Calvi A, MacManus D, Barkhof F, Chandran S, Weir CJ, Toosy A, Chataway J; MS-SMART trial investigators. De Angelis F, et al. J Neurol Neurosurg Psychiatry. 2024 Dec 18:jnnp-2024-334801. doi: 10.1136/jnnp-2024-334801. Online ahead of print. J Neurol Neurosurg Psychiatry. 2024. PMID: 39694820
Assessing the landscape and charting paths: UK neurology trainees' opinions on neuroinflammation subspecialty.
Arun T, Petheram K, Tallantyre E, Ford H, Chataway J, Dougall NM, Doshi A, Englezou C, Farrell R, Hughes S, McDonnell G, Murray K, Rees R, Robertson N, Schmierer K, Dobson R; Association of British Neurologists, Special interest group for MS and neuroinflammation. Arun T, et al. Among authors: ford h. Mult Scler Relat Disord. 2024 Dec;92:106144. doi: 10.1016/j.msard.2024.106144. Epub 2024 Nov 10. Mult Scler Relat Disord. 2024. PMID: 39579643
Using disease-modifying treatments in multiple sclerosis: Association of British Neurologists (ABN) 2024 guidance.
Rashid W, Ciccarelli O, Leary SM, Arun T, Doshi A, Evangelou N, Ford HL, Hobart J, Jacob S, Muraro PA, Murray K, Palace J, Dobson R; Association Of British Neurologists Multiple Sclerosis and Neuroinflammation Advisory Group. Rashid W, et al. Among authors: ford hl. Pract Neurol. 2024 Nov 11:pn-2024-004228. doi: 10.1136/pn-2024-004228. Online ahead of print. Pract Neurol. 2024. PMID: 39532459 Review.
921 results